High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID19 patients.
Acute-Phase Proteins
/ analysis
Antigens, CD
/ analysis
COVID-19
/ blood
Convalescence
Critical Illness
Cytokines
/ blood
Female
Follow-Up Studies
HLA-DR Antigens
/ analysis
Humans
Intensive Care Units
/ statistics & numerical data
Length of Stay
/ statistics & numerical data
Leukocyte Count
Lymphocyte Count
Lymphocyte Subsets
Male
Middle Aged
Monocytes
Neutrophils
Pandemics
Prognosis
Prospective Studies
SARS-CoV-2
COVID-19
CyTOF
Cytokine multiplexing
ICU patients
Immune profiling
Neutrophil-to-lymphocyte ratio
Recovering immune populations
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
28
10
2020
accepted:
03
03
2021
revised:
27
01
2021
pubmed:
15
3
2021
medline:
14
5
2021
entrez:
14
3
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic poses a major burden on healthcare and economic systems across the globe. Even though a majority of the population develops only minor symptoms upon SARS-CoV-2 infection, a significant number are hospitalized at intensive care units (ICU) requiring critical care. While insights into the early stages of the disease are rapidly expanding, the dynamic immunological processes occurring in critically ill patients throughout their recovery at ICU are far less understood. Here, we have analysed whole blood samples serially collected from 40 surviving COVID-19 patients throughout their recovery in ICU using high-dimensional cytometry by time-of-flight (CyTOF) and cytokine multiplexing. Based on the neutrophil-to-lymphocyte ratio (NLR), we defined four sequential immunotypes during recovery that correlated to various clinical parameters, including the level of respiratory support at concomitant sampling times. We identified classical monocytes as the first immune cell type to recover by restoration of HLA-DR-positivity and the reduction of immunosuppressive CD163 + monocytes, followed by the recovery of CD8 + and CD4 + T cell and non-classical monocyte populations. The identified immunotypes also correlated to aberrant cytokine and acute-phase reactant levels. Finally, integrative analysis of cytokines and immune cell profiles showed a shift from an initially dysregulated immune response to a more coordinated immunogenic interplay, highlighting the importance of longitudinal sampling to understand the pathophysiology underlying recovery from severe COVID-19.
Identifiants
pubmed: 33715015
doi: 10.1007/s00018-021-03808-8
pii: 10.1007/s00018-021-03808-8
pmc: PMC7955698
doi:
Substances chimiques
Acute-Phase Proteins
0
Antigens, CD
0
Cytokines
0
HLA-DR Antigens
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3987-4002Subventions
Organisme : KULeuven
ID : C14/17/084
Investigateurs
Michael Casaer
(M)
Dieter Dauwe
(D)
Jan Gunst
(J)
Greet Hermans
(G)
Stephanie Humblet-Baron
(S)
Diether Lambrechts
(D)
Adrian Liston
(A)
Natalie Lorent
(N)
Philippe Meersseman
(P)
Johan Neyts
(J)
Paul Proost
(P)
Jeroen Raes
(J)
Stephen Rex
(S)
Sabine Tejpar
(S)
Karin Thevissen
(K)
Thomas Tousseyn
(T)
Birgit Weynand
(B)
Alexander Wilmer
(A)
Carine Wouters
(C)
Références
Lancet. 1998 Feb 14;351(9101):467-71
pubmed: 9482437
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Front Immunol. 2020 Aug 18;11:2063
pubmed: 33013872
Front Med (Lausanne). 2020 Jun 09;7:301
pubmed: 32582743
Sci Immunol. 2020 Sep 17;5(51):
pubmed: 32943497
Front Microbiol. 2019 Dec 03;10:2752
pubmed: 31849894
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
Circulation. 2020 Sep 22;142(12):1176-1189
pubmed: 32755393
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
Cell Host Microbe. 2016 Feb 10;19(2):181-93
pubmed: 26867177
Nat Commun. 2021 Jul 5;12(1):4117
pubmed: 34226537
Drugs Context. 2020 May 19;9:
pubmed: 32499832
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
J Med Virol. 2020 Oct;92(10):1733-1734
pubmed: 32242950
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2103-2109
pubmed: 33161221
Nat Commun. 2020 Oct 16;11(1):5243
pubmed: 33067472
Nat Rev Immunol. 2017 Apr;17(4):233-247
pubmed: 28192415
Cell Rep Med. 2020 Aug 25;1(5):100078
pubmed: 32838342
Nat Rev Microbiol. 2010 May;8(5):350-60
pubmed: 20372157
J Virol. 2015 Apr;89(7):3859-69
pubmed: 25609809
Blood. 2012 Mar 29;119(13):3128-31
pubmed: 22310910
Anesth Analg. 2020 Jul;131(1):86-92
pubmed: 32243287
N Engl J Med. 2013 Jun 13;368(24):2277-85
pubmed: 23697469
Nat Rev Immunol. 2020 Sep;20(9):515-516
pubmed: 32728221
Int J Surg. 2020 Jul;79:43-46
pubmed: 32426019
Int J Mol Sci. 2020 May 14;21(10):
pubmed: 32423094
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926098
Thromb Res. 2020 Aug;192:3-8
pubmed: 32407937
J Exp Med. 2000 Jun 19;191(12):2159-70
pubmed: 10859340
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232303
Cell Death Differ. 2017 May;24(5):832-843
pubmed: 28234357
Crit Care. 2020 Jun 5;24(1):288
pubmed: 32503668
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
EBioMedicine. 2020 Jul;57:102885
pubmed: 32650275
Circ Res. 2019 Aug 2;125(4):470-488
pubmed: 31518165
Cell Host Microbe. 2020 Jun 10;27(6):870-878
pubmed: 32464097
J Leukoc Biol. 2014 May;95(5):723-731
pubmed: 24563509
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Crit Care Med. 1998 Nov;26(11):1793-800
pubmed: 9824069
Epidemiol Infect. 2020 Jul 09;148:e139
pubmed: 32641174
Clin Rheumatol. 2020 Jul;39(7):2077-2084
pubmed: 32472459
Rev Saude Publica. 2020;54:60
pubmed: 32491116
PLoS One. 2017 Apr 26;12(4):e0176460
pubmed: 28445506
Lancet Infect Dis. 2020 Oct;20(10):e261-e267
pubmed: 32711692
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
Crit Care. 2020 Nov 16;24(1):647
pubmed: 33198786
Science. 2015 Jul 17;349(6245):316-20
pubmed: 26185250
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
Blood. 2007 Feb 1;109(3):1131-7
pubmed: 16985170
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Front Immunol. 2020 Jul 03;11:1642
pubmed: 32719686
Cell Discov. 2020 May 4;6:31
pubmed: 32377375
PLoS One. 2020 Jul 9;15(7):e0235844
pubmed: 32645053
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
J Crit Care. 2020 Aug;58:96-97
pubmed: 32408107
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
JCI Insight. 2020 Jul 9;5(13):
pubmed: 32501293
Ther Clin Risk Manag. 2019 Jul 24;15:911-919
pubmed: 31413580